ESMO 2018 Targeting specific genomic mutation in breast cancer improves outcomes first study shows

ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

14:12 EDT 20 Oct 2018 | ecancermedicalscience

Targeting a common mutation in patients with hormone receptor positive (HR ) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival,...

More From BioPortfolio on "ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows"